Abstract
Invasive fungal infections are an actual problem of the modern medicine. This is due to the widening population of the affected patients and the increasing number of fungal strains that are resistant to the previously extensively used antifungal preparations. Candida spp. is the most frequent causative agents of invasive fungal infections. The emergence of echinocandins class was a breakthrough in the antifungal therapy because of their high activity against Candida spp. and some other pathogens, as well as their favorable safety profile. The recent IDSA and ESCMID recommendations in the treatment of Candida infections are strictly underline the necessity of the echinocandins administration in the majority of moderate and severe forms of Candida infections, also in patients with a history of the previous therapy with azoles. Anidulafungin after caspofungin and micafungin is a last of the registered in the market echinocandins representative, which possess good safety and tolerability profile, also a good efficacy in the therapy of invasive and esophageal candidiasis. The absence of clinically significant drugs interactions is especially important in patients with concomitant therapy, also in patients with renal or hepatic impairment as long as there are no requirements of anidulafungin dose adjustment in such categories of patients.
-
1.
Pfaller M., Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-63.
-
2.
Leleu G., Aegerter P., Guidet B., et al. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17:168-75.
-
3.
Almirante B., Rodríguez D., Park B.J., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43:1829-35.
-
4.
Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47:117-23.
-
5.
Pfaller M.A., Castanheira M., Messer S.A., et al. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 2010; 68:278-83.
-
6.
Dimopoulos G., Ntziora F., Rachiotis G., et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106:523-9.
-
7.
Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
-
8.
ESCMID diagnostic and management guideline for Candida disease 2011. Available at www.escmid.org.
-
9.
Merck & Co, INC. Caspofungin (Cancidas) Prescribing Information. Whitehouse Station, NJ: Merck & Co, INC., 2010.
-
10.
Astellas Pharma US, Inc. Micafungin (Mycamine) Prescribing Information. Deerfield, IL: Astellas Pharma US, Inc., 2010.
-
11.
Eschenauer G., Depestel D.D., Carver P.L. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3:71-97.
-
12.
Liu J., Balasubramanian M. 1,3-β-glucan synthase: a useful target for antifungal drugs. Curr Drug Tragets Infect Disord 2001; 1:159-69.
-
13.
EraxisTM (anidulafungin) for Injection. Prescribing information. Pfizer, New York, NY; 2010.
-
14.
Kurtz M.B., Heath I.B., Marrinan J., et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480-9.
-
15.
Colombo A., Ngai A.L., Bourque M., et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010; 54:1864-71.
-
16.
Horn D., Neofytos D., Anaissie E.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48:1695-703.
-
17.
Ghannoum M.A., Chen A., Buhari M., et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009; 15:274-9.
-
18.
Cota J., Carden M., Graybill J.R., et al. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006; 50:3926-8.
-
19.
Philip A., Odabasi Z., Rodriguez J., et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49:3572-4.
-
20.
Messer S.A., Jones R.N., Moet G.J., Kirby J.T., Castanheira M. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2010; 48:2984-7.
-
21.
Pongracz J., Kristof K. Species distribution, biofilm production, and antifungal susceptibility of Candida bloodstream isolates at a university hospital. Clin Microbiol Infect 2012; 18(Suppl. 3):175. Abstract # P838.
-
22.
Thye D., Shepherd B., White R.J., et al. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers (poster 36). Presented at: 41st Interscience Conference on Antimicrobial Agents; December 2001, Chicago.
-
23.
Damle B.D., Dowell J.A., Walsky R.L., et al. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009; 53:1149-56.
-
24.
Dowell J.A., Stogniew M., Krause D., Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharm 2007; 47:461-70.
-
25.
Burkhardt O., Kaever V., Burhenne H., Kielstein J.T. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009; 34:282-3.
-
26.
Crandon J.L., Banevicius M.A., Fang A.F., et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009; 53:5102-7.
-
27.
Benjamin D.K., Driscoll T., Seibel N.L., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632- 8.
-
28.
Dowell J.A., Stogniew M., Krause D., et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227-33.
-
29.
Dowell J.A., Schranz J., Baruch A., Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45:1373-82.
-
30.
Dowell J.A., Stogniew M., Krause D., et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47:305-14.
-
31.
Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-4.
-
32.
Pfaller M.A., Diekema D.J., Boyken L., et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agent Chemother 2005; 49:4795-7.
-
33.
Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-82.
-
34.
Ruhnke M., Paiva J., Meersseman W., et al. Anidulafungin for the treatment of candidemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 2012; 18:680-7.
-
35.
Vazquez J.A., Schranz J.A., Clark K., et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acqui Immune Defic Syndr 2008; 48:304-9.
-
36.
Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-5.
-
37.
Walsh T., Herbrecht R., Graham D., et al. Safety and tolerability of combination anidulafungin and liposomal amphotericin B for the treatment of invasive aspergillosis (poster). Presented at the 14th Focus on Fungal Infections Conference; 24-26 March 2004; New Orleans, LA.
-
38.
Marr K., Schlamm H., Rottinghaus S., et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Clin Microbiol Infect 2012; 18(Suppl. s3):713. Abstract # LB2812.
-
39.
Aguado J., Varo E., Usetti P., et al. Safety of anidulafungin in solid organ transplant recepients. Liver Transpl 2012; 18:680-5.
-
40.
Verma A., Auzinger G., Kantecki M., et al. Clinical experience with anidulafungin for the treatment of invasive fungal infections in patients with liver dysfunction and high incidence of multi organ failure - a single centre observational study. Clin Microbiol Infect 2012; 18(Suppl. s3):11. Abstract # O117.